Urgent.News

What's breaking now, across thousands of outlets.

Science

How research paved the way for progress in a rare form of ALS

An experimental ALS drug that grew out of basic and clinical research at Columbia University's Vagelos College of Physicians and Surgeons may soon become available for patients with a rare and aggressive form of the disease.

How research paved the way for progress in a rare form of ALS

A groundbreaking experimental ALS drug, ulefnersen, developed through research at Columbia University's Vagelos College of Physicians and Surgeons, has shown promising results in a rare and aggressive form of ALS known as FUS-ALS. This drug, a result of basic and clinical research, has successfully met its primary endpoint in the phase 3 FUSION trial, demonstrating significant improvement in patients with FUS-ALS compared to those who received a placebo.

FUS-ALS, caused by mutations in the FUS gene, affects only 1% to 2% of ALS patients but can be highly aggressive, often striking individuals in their prime. The drug, jacifusen, was developed after researchers showed that reducing levels of the toxic FUS protein could prevent or delay the onset and progression of the disease. The drug's effectiveness was first demonstrated in mouse models, with a young patient named Jaci Hermstad being the first human to receive the treatment.

Although Jaci passed away in 2020, her participation in the trial provided valuable insights into the drug's potential, paving the way for future advancements in ALS therapy.

Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Science

More from Thursday 19 November →